文献速递免疫规划传染病防控与疫情报告妇幼与学校卫生

婴幼儿与学龄前儿童EV-A71灭活疫苗免疫原性与安全性Ⅱb期试验

Immunogenicity and safety of an inactivated enterovirus A71 vaccine in children 3-6 years and 2-35 months of age- an open-label, randomized phase IIb clinical trial.
PubMed 文献 · Vaccine · 2019-08-06

该开放标签、多中心、随机Ⅱb期试验评估含铝佐剂全病毒EV-A71灭活疫苗在2月龄至6岁儿童中的免疫原性与安全性,共135名儿童完成两剂接种。含佐剂0.5 μg与1.0 μg总病毒蛋白均诱导显著中和抗体升高,两剂后血清转化率达93.75%–100.0%,含佐剂1.0 μg组抗体滴度高于0.5 μg组,而无佐剂1.0 μg组无免疫原性,未报告重大不良事件。

要点

  • 含佐剂0.5 μg与1.0 μg总病毒蛋白两剂后血清转化率达93.75%–100.0%。
  • 含佐剂1.0 μg组中和抗体滴度高于含佐剂0.5 μg组。
  • 无佐剂1.0 μg总病毒蛋白未显示免疫原性。

核心结论

  • 含佐剂EV-A71灭活疫苗在2月龄至6岁儿童中具有免疫原性且安全性良好。

研究设计与样本

  • 开放标签、多中心、随机Ⅱb期临床试验,分A、B两部分,共135名儿童完成两剂免疫,A部分58名、B部分77名。
  • A部分纳入36月龄至6岁儿童随机分3组,分别接种含Al(OH)3佐剂0.5 μg总病毒蛋白、含Al(OH)3佐剂1.0 μg总病毒蛋白或不含佐剂1.0 μg总病毒蛋白,两剂间隔28天。
  • B部分在A部分安全性无担忧后按同一方案纳入2月龄至35月龄儿童。

主要发现

  • 含佐剂0.5 μg与1.0 μg总病毒蛋白均使中和抗体滴度显著升高,两剂后血清转化率达93.75%–100.0%。
  • 含佐剂1.0 μg总病毒蛋白诱导的中和抗体滴度高于含佐剂0.5 μg总病毒蛋白。
  • 不含佐剂1.0 μg总病毒蛋白无免疫原性。
  • 未报告重大不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Enterovirus A71 (EV-A71) infection can cause severe debilitating complications and even death in young children. The immunogenicity and safety of an inactivated whole EV-A71 virus vaccine were assessed in children 2 months to 6 years of age. METHODS: This was an open-label, multi-center and randomized phase IIb study, which divided into part A and B. In part A, children 36 months to 6 years of age were enrolled and randomized into 3 groups, receiving 0.5 μg total viral protein (TP) with adjuvant Al(OH)3, 1.0 μg TP with Al(OH)3 or 1.0 μg TP only. Two doses of vaccines were administered at a 28-day interval and blood was taken before immunization, at week 4, 8, 28 and 52 (optional) for virus neutralization assay. Safety profiles were also monitored. After safety profiles had shown no concerns, children 2 months to 35 months of age (part B) were subsequently enrolled following the same protocol. RESULTS: A total of 135 children completed two doses of immunization, including 58 in part A and 77 in part B. Both adjuvanted 0.5 μg and 1.0 μg TP elicited significant raise of neutralizing antibody titers and seroconversion rate was up to 93.75-100.0% after 2 doses of immunization. Adjuvanted 1.0 μg TP induced higher titers of neutralizing antibodies than adjuvanted 0.5 μg TP. By contrast, non-adjuvanted 1.0 μg TP was not immunogenic. No major adverse events were reported. CONCLUSIONS: This EV-A71 vaccine containing adjuvant is immunogenic and safe in children 2 months to 6 years of age. CLINICAL TRIALS REGISTRATION: NCT03268083.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hung MC, Cho CY, Chen CJ, et al. Immunogenicity and safety of an inactivated enterovirus A71 vaccine in children 3-6 years and 2-35 months of age- an open-label, randomized phase IIb clinical trial. Vaccine. 2019. PMID: 31399275. doi:10.1016/j.vaccine.2019.07.096

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。